Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Executive Summary

Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.


Related Content

Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
EpiPen Competitor Auvi-Q Relauching With Ultimate Copay: $0
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny
Regrets For Valeant's Ackman, Pearson; Big Pay For Papa
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
It Was Shkreli's Show, But Pharma Was On Trial
Biotech Walloped On Clinton Drug Price Controls Threat


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts